Entrada Therapeutics, Inc.
TRDAHealthcare|Biotechnology|US
$4.89
+0.34 (+7.47%)
DCF Value
$9.63
Tangible Book / Share
$4.68
Cash / Share
$4.56
Financials
Financial Snapshot
Market Cap
$190.4M
Enterprise Value
$125.5M
Revenue (TTM)
$4.0M
Net Income (TTM)
-$161.4M
Cash & Investments
$193.0M
Net Cash
$145.7M
Free Cash Flow (TTM)
-$136.3M
Operating CF (TTM)
-$136.3M
Debt/Equity
0.24
Cash Runway & Burn Rate
Cash on Hand
$193.0M
Quarterly Burn
$34.1M
Monthly Burn
$11.4M
Est. Runway
~5.7 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $16.8M | $39.0M | $291.1M | $188.7M | $352.0M | $420.0M | $295.7M | $193.0M | |
| Operating Cash Flow | -$10.8M | -$25.6M | -$50.9M | -$93.8M | $139.8M | -$41.6M | -$128.5M | -$136.3M | |
| Free Cash Flow | -$11.4M | -$27.9M | -$55.4M | -$96.7M | $134.2M | -$44.7M | -$129.6M | -$136.3M | |
| Capital Expenditure | -$630.0K | -$2.3M | -$4.6M | -$2.9M | -$5.6M | -$3.2M | -$1.0M | -$9.0K | |
| Financing Cash Flow | $38.0K | $50.1M | $307.5M | $479.0K | $21.0M | $103.0M | $887.0K | $642.0K |
R&D Spending
R&D (TTM)
$134.7M
R&D Intensity
3388.2%
R&D Growth vs Prior
-5.3%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $129.0M | $210.8M | $25.4M | $4.0M | |
| R&D Expense | $8.2M | $21.1M | $35.9M | $66.6M | $99.9M | $125.3M | $142.3M | $134.7M | |
| R&D % of Revenue | — | — | — | — | 77.4% | 59.4% | 559.7% | 3388.2% | |
| SG&A | $3.6M | $5.2M | $15.2M | $30.6M | $32.3M | $38.5M | $41.0M | $40.4M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $129.0M | $210.8M | $25.4M | $4.0M | |
| Cost of Revenue | $104.0K | $326.0K | $0.00 | $0.00 | $0.00 | $0.00 | $4.1M | $1.7M | |
| Gross Profit | -$104.0K | -$326.0K | $0.00 | $0.00 | $129.0M | $210.8M | $21.3M | $2.3M | |
| R&D | $8.2M | $21.1M | $35.9M | $66.6M | $99.9M | $125.3M | $142.3M | $134.7M | |
| SG&A | $3.6M | $5.2M | $15.2M | $30.6M | $32.3M | $38.5M | $41.0M | $40.4M | |
| Operating Income | -$11.8M | -$26.7M | -$51.1M | -$97.2M | -$3.2M | $47.0M | -$156.0M | -$171.2M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $2.6M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$5.1M | -$26.5M | -$51.2M | -$94.6M | $12.1M | $66.5M | -$142.8M | -$161.2M | |
| Net Income | -$4.6M | -$26.5M | -$51.2M | -$94.6M | -$6.7M | $65.6M | -$143.8M | -$161.4M | |
| EPS (Diluted) | -4.44 | -0.84 | -1.60 | -2.79 | -0.20 | 1.68 | -3.47 | -3.85 | |
| EBITDA | -$11.7M | -$26.2M | -$50.0M | -$90.1M | $14.9M | $70.3M | -$138.7M | -$162.3M | |
| Shares Out. (M) | 1.05 | 31.25 | 31.22 | 31.29 | 33.05 | 39.00 | 41.37 | 42.37 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16.8M | $39.0M | $291.1M | $45.2M | $67.6M | $101.2M | $90.4M | $112.2M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $143.6M | $284.4M | $318.8M | $205.3M | $80.8M | |
| Total Current Assets | $17.4M | $39.9M | $298.7M | $209.9M | $369.8M | $440.0M | $306.3M | $203.0M | |
| Total Assets | $18.2M | $43.5M | $305.8M | $252.1M | $469.2M | $526.3M | $377.4M | $266.9M | |
| Total Current Liabilities | $1.9M | $3.4M | $6.7M | $22.0M | $158.8M | $39.5M | $24.5M | $25.9M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $33.8M | $85.0M | $7.1M | $39.5M | $226.8M | $97.6M | $71.2M | $68.6M | |
| Stockholders' Equity | -$15.5M | -$41.5M | $298.7M | $212.6M | $242.4M | $428.7M | $306.1M | $198.3M | |
| Retained Earnings | -$16.0M | -$42.5M | -$93.7M | -$188.3M | -$195.0M | -$129.3M | -$273.1M | -$395.3M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$10.8M | -$25.6M | -$50.9M | -$93.8M | $139.8M | -$41.6M | -$128.5M | -$136.3M | |
| Capital Expenditure | -$630.0K | -$2.3M | -$4.6M | -$2.9M | -$5.6M | -$3.2M | -$1.0M | -$9.0K | |
| Free Cash Flow | -$11.4M | -$27.9M | -$55.4M | -$96.7M | $134.2M | -$44.7M | -$129.6M | -$136.3M | |
| Investing Cash Flow | -$630.0K | -$2.3M | -$4.6M | -$148.7M | -$138.4M | -$27.8M | $116.8M | $154.0M | |
| Financing Cash Flow | $38.0K | $50.1M | $307.5M | $479.0K | $21.0M | $103.0M | $887.0K | $642.0K | |
| Issuance of Stock | $38.0K | $0.00 | $190.7M | $479.0K | $19.4M | $99.6M | $887.0K | $192.0K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $294.0K | $325.0K | $2.5M | $9.9M | $13.1M | $17.9M | $19.6M | $19.0M | |
| Net Change in Cash | $16.8M | $22.2M | $252.0M | -$245.9M | $22.4M | $33.6M | -$10.8M | $18.3M |
Dilution Tracker
Shares outstanding grew 32.4% over 5 years — significant dilution
Shares Outstanding
39M
5-Year Share Growth
+32.4%
Stock Issuance (TTM)
$192.0K
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1.05 | 31.25 | 31.22 | 31.29 | 33.05 | 39.00 | 41.37 | 42.37 | |
| Change vs Prior % | — | 2881.7% | -0.1% | 0.2% | 5.6% | 18.0% | 6.1% | 2.4% | |
| Stock Issuance | $38.0K | $0.00 | $190.7M | $479.0K | $19.4M | $99.6M | $887.0K | $192.0K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $294.0K | $325.0K | $2.5M | $9.9M | $13.1M | $17.9M | $19.6M | $19.0M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | 100.0% | 100.0% | 83.9% | 57.5% | |
| Operating Margin % | — | — | — | — | -2.5% | 22.3% | -613.7% | -4303.8% | |
| Net Margin % | — | — | — | — | -5.2% | 31.1% | -565.5% | -4058.0% | |
| EBITDA Margin % | — | — | — | — | 11.5% | 33.3% | -545.7% | -4081.8% | |
| FCF Margin % | — | — | — | — | 104.0% | -21.2% | -509.6% | -3428.1% | |
| ROE % | 30.0% | 63.9% | -17.1% | -44.5% | -2.8% | 15.3% | -47.0% | -64.0% | |
| ROA % | -25.5% | -60.9% | -16.7% | -37.5% | -1.4% | 12.5% | -38.1% | -60.5% | |
| ROIC % | -72.5% | -66.4% | -17.1% | -40.8% | 0.6% | 9.4% | -43.7% | -69.7% | |
| R&D / Revenue % | — | — | — | — | 77.4% | 59.4% | 559.7% | 3388.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 63.4% | -87.9% | |
| Gross Profit | 0.0% | -213.5% | 100.0% | 0.0% | 0.0% | 63.4% | -89.9% | |
| Operating Income | 0.0% | -125.5% | -91.7% | -90.2% | 96.7% | 1586.7% | -431.8% | |
| Net Income | 0.0% | -470.5% | -92.9% | -84.9% | 92.9% | 1081.7% | -319.0% | |
| EPS (Diluted) | 0.0% | 81.1% | -90.5% | -74.4% | 92.8% | 940.0% | -306.5% | |
| Operating Cash Flow | 0.0% | -136.7% | -98.9% | -84.4% | 249.1% | -129.7% | -209.2% | |
| Free Cash Flow | 0.0% | -144.0% | -98.8% | -74.4% | 238.8% | -133.3% | -189.7% | |
| R&D Expense | 0.0% | 156.8% | 70.2% | 85.4% | 50.0% | 25.5% | 13.5% | |
| SG&A Expense | 0.0% | 45.2% | 190.2% | 101.6% | 5.4% | 19.1% | 6.7% | |
| Total Assets | 0.0% | 138.7% | 602.6% | -17.6% | 86.1% | 12.2% | -28.3% | |
| Book Value / Share | 0.0% | 91.0% | 820.5% | -29.0% | 8.0% | 56.7% | -35.6% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 163.1% | -13.2% | -14.0% | |
| Diluted Shares | 0.0% | 2881.7% | -0.1% | 0.2% | 5.6% | 18.0% | 6.1% |
Valuation
P/E (TTM)At Loss
P/S47.88
10Y Low / Med / High3.06 / 3.87 / 16.73
P/B1.04
10Y Low / Med / High1.39 / 1.79 / 2.06
EV/EBITDAAt Loss
EV/Revenue31.55
10Y Low / Med / High2.86 / 3.87 / 15.18
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$9.63
Tangible Book / Share
$4.68
Net Current Assets / Share
$3.45
Graham Net-Net
$2.95
Cash / Share
$4.56
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -5.39 | -28.51 | -10.70 | -4.85 | -75.45 | 9.82 | -2.96 | -1.27 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 3.87 | 3.06 | 16.73 | 47.88 | |
| P/B Ratio | -1.62 | -18.04 | 1.79 | 1.99 | 2.06 | 1.50 | 1.39 | 1.04 | |
| EV/EBITDA | -0.70 | -27.08 | -4.87 | -4.48 | 33.52 | 8.58 | -2.78 | -0.77 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 3.87 | 2.86 | 15.18 | 31.55 |
Analyst Estimates & Quality
Altman Z-Score
-1.59
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $6.8M | $17.5M | $20.9M |
| Net Income | -$168.6M | -$171.9M | -$124.9M |
| EPS | $-4.01 | $-3.58 | $-3.19 |
| # Analysts (EPS) | 3 | 5 | 5 |
Revenue Segments
By Product
| Segment | 2023 | 2024 | 2025 |
|---|---|---|---|
| License | $139.0M | $20.2M | $300.0K |